Vaxcyte 3Q 2026: Net loss $297M, EPS $(1.99) — 10-Q Summary

What happened

Vaxcyte reported a $297 million net loss in the third quarter of 2026, compared with a $213 million loss a year earlier, and loss per share of $1.99 versus $1.56. Its VAX-31 vaccine met all primary endpoints in a Phase 3 trial, and a manufacturing suite began operating in August.

Confirmed

Global impact / market context

The wider loss and higher research costs show that advancing trials and preparing manufacturing are consuming more cash. Positive VAX-31 trial results and completed enrollment in follow-up studies could support future development, but further results and spending will shape the path toward possible launches.

Analyst inference

Vaxcyte is balancing a larger current loss against progress in vaccine testing and production capacity. The new manufacturing suite supports PCV vaccine production, while data expected in the first half of 2027 may clarify clinical progress; neither item establishes commercial sales or profitability.

Analyst inference

What to watch

1. Watch for OPUS-2 and OPUS-3 trial data expected in the first half of 2027, which could provide further evidence about VAX-31’s performance. Confirmed
2. Track infant Phase 2 results for VAX-31, also expected in the first half of 2027, for information on its development in infants. Confirmed
3. Monitor research spending and manufacturing activity: continued increases could deepen losses and use cash, while trial progress may support later development and potential launches. Analyst inference

Evidence

• Original source link unavailable